X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (29) 29
hematology (23) 23
female (21) 21
transplantation (21) 21
index medicus (20) 20
male (20) 20
middle aged (19) 19
adult (18) 18
aged (17) 17
immunology (16) 16
hematology, oncology and palliative medicine (13) 13
retrospective studies (8) 8
treatment outcome (8) 8
hematopoietic stem cell transplantation (7) 7
hematopoietic stem cell transplantation - adverse effects (7) 7
hematopoietic stem cells (7) 7
stem cells (7) 7
transplantation, homologous (7) 7
versus-host-disease (7) 7
bone-marrow-transplantation (6) 6
cord blood transplantation (6) 6
hematologic neoplasms - therapy (6) 6
risk factors (6) 6
adolescent (5) 5
adult patients (5) 5
antifungal agents - therapeutic use (5) 5
care and treatment (5) 5
graft survival (5) 5
health aspects (5) 5
medicine & public health (5) 5
microbiology (5) 5
mucormycosis (5) 5
oncology (5) 5
prophylaxis (5) 5
recipients (5) 5
survival analysis (5) 5
unrelated donors (5) 5
antiviral agents - therapeutic use (4) 4
bone-marrow (4) 4
cancer (4) 4
chemotherapy (4) 4
cord blood stem cell transplantation - adverse effects (4) 4
hematological malignancies (4) 4
immunosuppressive agents - adverse effects (4) 4
infections (4) 4
invasive fungal infections (4) 4
japan (4) 4
mortality (4) 4
recurrence (4) 4
stem-cell transplantation (4) 4
surgery (4) 4
transplantation conditioning (4) 4
transplantation conditioning - methods (4) 4
young adult (4) 4
aged, 80 and over (3) 3
alemtuzumab (3) 3
allogeneic hematopoietic stem cell transplantation (3) 3
antibodies, monoclonal, humanized (3) 3
antifungal agents - administration & dosage (3) 3
blood (3) 3
cord blood (3) 3
cord blood stem cell transplantation (3) 3
cytomegalovirus (3) 3
engraftment (3) 3
graft vs host disease - etiology (3) 3
graft vs host disease - mortality (3) 3
hematologic malignancies (3) 3
hematologic neoplasms - complications (3) 3
immunocompromised host (3) 3
immunosuppressive agents - administration & dosage (3) 3
infection (3) 3
infectious diseases (3) 3
invasive fungal-infections (3) 3
liposomal-amphotericin b (3) 3
medical research (3) 3
medicine, experimental (3) 3
micafungin (3) 3
mucormycosis - diagnosis (3) 3
myeloablative agonists - therapeutic use (3) 3
pharmacology & pharmacy (3) 3
preemptive therapy (3) 3
risk-factors (3) 3
stem cell transplantation (3) 3
survival (3) 3
susceptibility (3) 3
therapy (3) 3
transplants & implants (3) 3
vidarabine - administration & dosage (3) 3
vidarabine - analogs & derivatives (3) 3
abridged index medicus (2) 2
acute disease (2) 2
allografts (2) 2
amphotericin b (2) 2
amphotericin b - administration & dosage (2) 2
analysis (2) 2
antibodies (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibodies, neoplasm - adverse effects (2) 2
antifungal agents (2) 2
antifungal agents - pharmacology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Medical Mycology Journal, ISSN 2185-6486, 2017, Volume 58, Issue 3, pp. E97 - E105
The risk of invasive fungal infections (IFIs) is extremely high in patients with hematological malignancies due to the prolonged and profound neutropenia and... 
Prophylaxis | Stem cell transplantation | Patients | Hematopoietic stem cells | Hemopoiesis | Mucormycosis | Chemotherapy | Immunosuppression | Amphotericin B | Surgery | Aspergillosis | Diagnosis | Neutropenia
Journal Article
Medical Mycology Journal, ISSN 2185-6486, 2017, Volume 58, Issue 3, pp. E97 - E105
Journal Article
Medical Mycology Journal, ISSN 2185-6486, 2017, Volume 58, Issue 3, pp. E97 - E105
The risk of invasive fungal infections (IFIs) is extremely high in patients with hematological malignancies due to the prolonged and profound neutropenia and... 
hematological malignancies | invasive fungal infections | mucormycosis | liposomal-amphotericin B
Journal Article
[Rinsho ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 2017, Volume 58, Issue 12, p. 2450
As the number of long-term survivors after allogeneic hematopoietic stem cell transplantation (HSCT) has increased owing to advances in transplantation and... 
Journal Article
Medical Mycology Journal, ISSN 2185-6486, 2016, Volume 57, Issue 4, pp. J155 - J162
Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 08/2016, Volume 16, Issue 1, p. 372
Journal Article
[Rinsho ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 01/2016, Volume 57, Issue 10, pp. 2208 - 2217
Journal Article
[Rinsho ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 2016, Volume 57, Issue 10, p. 2208
Invasive fungal infections (IFIs) are one of the most serious complications developing after allogeneic hematopoietic stem cell transplantation (allo-HSCT).... 
Humans | Risk Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Invasive Fungal Infections - etiology | Invasive Fungal Infections - prevention & control | Transplantation, Homologous | Antifungal Agents - therapeutic use
Journal Article
Mycopathologia, ISSN 0301-486X, 10/2017, Volume 182, Issue 9, pp. 847 - 853
Infection caused by Cunninghamella bertholletiae carries one of the highest mortality rates among mucormycosis, and there are no reported cases that survived... 
Life Sciences | Medical Microbiology | Microbial Ecology | Mucormycosis | Liposomal amphotericin B | Microbiology | Cunninghamella bertholletiae | Cord blood transplantation | Micafungin | Plant Sciences | Eukaryotic Microbiology | POSACONAZOLE | ZYGOMYCOSIS | PNEUMONIA | CHILD | THERAPY | BONE-MARROW TRANSPLANT | INFECTION | PATIENT | MYCOLOGY | OF-THE-LITERATURE | LYMPHOBLASTIC-LEUKEMIA | Lung Diseases, Fungal - diagnosis | Humans | Male | Transplant Recipients | Lung Diseases, Fungal - microbiology | Echinocandins - administration & dosage | Cord Blood Stem Cell Transplantation - adverse effects | Lung Diseases, Fungal - drug therapy | Amphotericin B - administration & dosage | Adult | Female | Mucormycosis - surgery | Drug Therapy, Combination | Mucormycosis - drug therapy | Immunosuppressive Agents - administration & dosage | Mucormycosis - diagnosis | Lung Diseases, Fungal - surgery | Treatment Outcome | Cunninghamella - isolation & purification | Mucormycosis - microbiology | Immunosuppressive Agents - adverse effects | Aged | Immunocompromised Host | Lipopeptides - administration & dosage | Lung - surgery | Antifungal Agents - administration & dosage | Care and treatment | Amphotericin B | Stem cells | Antiparasitic agents | Respiratory agents | Dosage and administration | Transplantation | Health aspects | Immunosuppressive agents | Hematopoietic stem cells | Fungicides | Transplants & implants | Syngeneic grafts | Therapeutic applications | Neutrophils | Lung transplantation | Stem cell transplantation | Infections | Blood | Hemopoiesis | Allografts | Cord blood | Diagnostic systems | Immunocompromised hosts | Health risk assessment | Index Medicus
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 05/2018, Volume 62, Issue 5
Journal Article
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, ISSN 1083-8791, 03/2018, Volume 24, Issue 3, pp. S231 - S232
Conference Proceeding
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 11, pp. 2008 - 2016
Abstract Cytomegalovirus (CMV) infection is a major infectious complication after allogeneic hematopoietic cell transplantation (allo-HSCT). Recently, it was... 
Hematology, Oncology and Palliative Medicine | Cytomegalovirus | Risk of relapse | Allogeneic hematopoietic stem cell transplantation | Nonrelapse mortality | DONOR | BONE-MARROW | IMMUNOLOGY | RECIPIENTS | VERSUS-HOST-DISEASE | SEROSTATUS | TRANSPLANTATION | cell transplantation | IMPACT | CMV REACTIVATION | DOUBLE-BLIND | INFECTION | RETROSPECTIVE ANALYSIS | HEMATOLOGY | Allogeneic hematopoietic stem | Graft vs Host Disease - therapy | Myeloablative Agonists - therapeutic use | Recurrence | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Cytomegalovirus Infections - immunology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Leukemia, Myeloid, Acute - immunology | Graft vs Host Disease - immunology | Transplantation, Homologous | Cytomegalovirus Infections - mortality | Myelodysplastic Syndromes - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Societies, Medical | Graft vs Host Disease - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Cytomegalovirus Infections - virology | Adult | Female | Unrelated Donors | Retrospective Studies | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Japan | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Cytomegalovirus - immunology | Adolescent | Myelodysplastic Syndromes - mortality | Cytomegalovirus Infections - therapy | Aged | Transplantation Conditioning | Myelodysplastic Syndromes - pathology | Virus Activation - immunology | Myelodysplastic Syndromes - immunology | Care and treatment | Relapse | Stem cells | Cytomegalovirus infections | Transplantation | Health aspects | Risk factors | Hematopoietic stem cells | Diseases
Journal Article
International Journal of Hematology, ISSN 0925-5710, 5/2014, Volume 99, Issue 5, pp. 652 - 658
Despite the recent introduction of a new class of anti-Aspergillus agents, no standard regimen for the prevention of invasive fungal disease (IFD) following... 
Oncology | Medicine & Public Health | Hematology | Voriconazole | Prophylaxis | Cord blood transplantation | ADULT PATIENTS | INFECTIONS | COMPARING METHOTREXATE | BONE-MARROW-TRANSPLANTATION | INTENSITY | RECIPIENTS | VERSUS-HOST-DISEASE | ANTIFUNGAL AGENTS | STEM-CELL TRANSPLANTATION | HEMATOLOGY | EPIDEMIOLOGY | Antifungal Agents - adverse effects | Prospective Studies | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Antifungal Agents - therapeutic use | Young Adult | Cord Blood Stem Cell Transplantation - adverse effects | Drug Interactions | Antifungal Agents - pharmacokinetics | Aged, 80 and over | Adult | Female | Transplantation Conditioning - adverse effects | Graft vs Host Disease - etiology | Mycoses - prevention & control | Hematologic Diseases - complications | Voriconazole - adverse effects | Risk Factors | Voriconazole - therapeutic use | Graft Survival | Vidarabine - analogs & derivatives | Hematologic Diseases - therapy | Voriconazole - pharmacokinetics | Graft vs Host Disease - drug therapy | Mycoses - diagnosis | Aged | Vidarabine - administration & dosage | Mycoses - etiology | Premedication | Prevention | Antimitotic agents | Medical research | Corticosteroids | Stem cells | Mycoses | Medicine, Experimental | Transplantation | Antineoplastic agents | Health aspects | Hematopoietic stem cells
Journal Article
Journal of Medical Virology, ISSN 0146-6615, 10/2008, Volume 80, Issue 10, pp. 1769 - 1775
Addition of in vivo alemtuzumab to the conditioning regimen enabled 2‐ or 3‐locus‐mismatched hematopoietic stem cell transplantation with an acceptable... 
hematopoietic stem cell transplantation | mutation | alemtuzumab | CMV | resistance | Resistance | Alemtuzumab | Mutation | Hematopoietic stem cell transplantation | AZATHIOPRINE | PREEMPTIVE THERAPY | PP65 ANTIGENEMIA | DNA-POLYMERASE | CHILDREN | INHIBITS REPLICATION | HERPES-SIMPLEX-VIRUS | VIROLOGY | DISEASE | GANCICLOVIR | CHRONIC LYMPHOCYTIC-LEUKEMIA | Cytosine - analogs & derivatives | Foscarnet - pharmacology | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Cytomegalovirus Retinitis - etiology | Molecular Sequence Data | Male | Anemia, Refractory, with Excess of Blasts - surgery | DNA-Directed DNA Polymerase - genetics | Microbial Sensitivity Tests | Antibodies, Monoclonal, Humanized | Cytomegalovirus Retinitis - virology | Cytomegalovirus Retinitis - drug therapy | Point Mutation - drug effects | Base Sequence | Ganciclovir - therapeutic use | Ganciclovir - pharmacology | Cytosine - pharmacology | Cytosine - therapeutic use | Immunosuppressive Agents - administration & dosage | Cytomegalovirus - genetics | Cytomegalovirus - isolation & purification | Antiviral Agents - pharmacology | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Hematopoietic Stem Cell Transplantation | Viral Proteins - genetics | Phosphotransferases (Alcohol Group Acceptor) - genetics | Antibodies, Neoplasm - administration & dosage | Cytomegalovirus Retinitis - prevention & control | Drug Resistance, Viral - genetics | Organophosphonates - pharmacology | Virus Activation - drug effects | Antibodies, Monoclonal - administration & dosage | Immunosuppressive Agents - adverse effects | Foscarnet - therapeutic use | Antibodies, Neoplasm - adverse effects | Cytomegalovirus - drug effects
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2017, Volume 23, Issue 3, pp. S178 - S178
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.